Business ❯Pharmaceuticals

Drug Development

Drug Development Pharmaceuticals Treatment Options Patient Care Market Competition Pharmaceuticals Obesity Clinical Trials FDA Drug Development

GSK Acquires Promising Liver Disease Drug Efimosfermin in $2 Billion Deal

The acquisition strengthens GSK's hepatology pipeline with a potential best-in-class treatment targeting a 2029 market launch.

Novo Nordisk Revises 2025 Outlook as FDA Crackdown and Competition Reshape Wegovy Market

AstraZeneca Reports Q1 Growth and Expands US Investments Amid Regulatory Challenges

Novo Nordisk Seeks FDA Approval as Eli Lilly's Weight-Loss Pill Advances

Pfizer Halts Development of Oral Weight-Loss Pill After Liver Injury

Novo Nordisk Faces Investor Turmoil as Wegovy Sales and Market Share Decline

Federal Investigation Examines Claims of Pfizer Vaccine Announcement Delay in 2020

Eli Lilly's Mounjaro Launches in India, Targeting Obesity and Diabetes

NHS Approves First Daily Pill for Endometriosis Treatment

Roche and Zealand Partner in $5.3 Billion Deal for Obesity Drug Development

Novo Nordisk's CagriSema Falls Short in Latest Weight-Loss Trial for Diabetes Patients

AbbVie Enters Obesity Drug Market with $2.2 Billion Licensing Deal

FDA to Decide on First Twice-Yearly HIV Prevention Shot by June

Novo Nordisk Reports Doubling Wegovy Sales, Projects Slower Growth in 2025

Bristol Myers Squibb Predicts 2025 Revenue Decline, Expands Cost-Cutting Measures

Merck Cuts 2025 Revenue Forecast After Halting Gardasil Shipments to China

UK Tightens Rules for Online Prescriptions of Weight-Loss Drugs

Novo Nordisk's Amycretin Shows 22% Weight Loss in Trial, Boosting Stock